National Hepatitis C Program | | | |
| In the Literature | | | | |
| Previous Articles by Topic | | | Epidemiology & Natural Science | | | Antibody to hepatitis B core antigen and risk for hepatitis C-related hepatocellular carcinoma: a prospective study. Ikeda K, et al. Ann Intern Med. 2007 May 1;146(9):649-56. | | | Elevated prevalence of hepatitis C infection in users of United States veterans medical centers Dominitz JA, et al. Hepatology. 2005;41:88-96. | | | Hepatitis C tested prevalence and comorbidities among veterans in the US Northwest Sloan KL, et al. J Clin Gastroenterol. 2004 Mar;38(3):279-84. | | | Diagnosis, management, and treatment of hepatitis C Strader DB, et al. Hepatology. 2004 Apr;39(4):1147-71. | | | CDC: Prevalence of hepatitis C virus infection among clients of HIV counseling and testing sites -- Connecticut, 1999 Morbidity and Mortality Weekly Report, July 13, 2001. | | | CDC: Hepatitis C virus infection among firefighters, emergency medical technicians, and paramedics -- selected locations, United States, 1991-2000 Morbidity and Mortality Weekly Report, July 28, 2000. | |
|
| Prevention & Transmission | | |
| Testing & Counseling | | |
| Clinical Management | | |
| Treatment | | | Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. Di Bisceglie AM, et al. N Engl J Med. 2008 Dec 4;359(23):2429-41. | | | Racial differences in the evaluation and treatment of hepatitis C among veterans: a retrospective cohort study. Rousseau CM, Ioannou GN, Todd-Stenberg JA, et al. Am J Public Health. 2008 May;98(5):846-52. | | | Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Kieffer TL, et al. Hepatology. 2007 Sep;46(3):631-9. | | | Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C. Forestier N, et al. Hepatology. 2007 Sep;46(3):640-8. | | | Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Shiffman ML, et al. Gastroenterology. 2007 Jan;132(1):103-12. | | | Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. Mangia A, et al. N Engl J Med. 2005 Jun 23;352(25):2609-17. | | | Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites Muir AJ, et al. N Engl J Med. 2004 May 27;350(22):2265-71. | | | Neuropsychiatric side effects of HCV therapy and their treatment: focus on IFNa-induced depression. Hauser, P. Gastroenterology Clin N Am. 2004; 33;S37-S50. | | | A prospective study of neuropsychiatric symptoms associated with interferon-alpha-2b and ribavirin therapy for patients with chronic hepatitis C. Dieperink E, Ho SB, Thuras P, Willenbring ML. Psychosomatics. 2003 Mar-Apr;44(2):104-12. | |
|
| HIV Coinfection | | |
| Hepatitis C and Associated Diseases | | |
| Other Types of Hepatitis | | |
| Cirrhosis | | |
| Hepatocellular Carcinoma | | |
| Liver Transplant | | |
|
|
| | | |
|
| | |
|
Reviewed/Updated Date: December 29, 2008 |
|